The blood-brain-barrier (BBB) forms a boundary between the peripheral blood and the central nervous system. It is commonly impaired in neurological diseases such as multiple sclerosis and ischemic stroke, and insufficient barrier function of the BBB can result in neuroaxonal damage. The aim of this project is to elucidate easily measurable markers for both impairment and physiological function of the BBB, which could be used to monitor the success of approved therapies as well as to develop new treatment paradigms. Furthermore, we will use animal models of multiple sclerosis and ischemic stroke to evaluate the potential positive effect of regulating neuronal excitability on neuroaxonal damage. 

Here you can get further information.
The latest press release can be found here.